In Massachusetts, InVivo Therapeutics Holdings Corp., a biomaterials and biomedicals company focused on spinal cord injuries, hired Christopher McNulty as CFO as of March 29th. McNulty was a former SVP of Business Development and Investor Relations at InVivo and worked directly on a follow-on offering and direct financing projects. Prior to InVivo, he worked at Repligen leading its acquisition of Novozymes Sweden, and seemingly is a jack of all trades with degrees in electrical engineering and computer science from MIT as well as an MBA from Harvard. Melanie Morel-Ferris has been serving as the interim CFO and will stay on as Senior Director of Finance and Controller.
Latest article
Chupps commissions disappearing billboard to spotlight its biodegradable sandals
In India, footwear brand Chupps has created a sandal-shaped billboard that is made to disappear over time.
The unique advertisement, which is located in...
CJ Biomaterials to supply PHAs for biobased turf
In South Korea, CJ Biomaterials has partnered with Sweden’s BIQ Materials to produce artificial turf infill made with CJ’s PHACT™ polyhydroxyalkanoate.
Infill, commonly used...
New York “Living Room” exhibit spotlights sustainable materials in domestic design
In New York, an exhibit at Fugue Gallery is spotlighting the potential of renewable and reclaimed materials in design.
Curated by Helena Elston, Living...